Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[WHO-classification of malignant lymphomas].

T Rüdiger¹, H K Müller-Hermelink

¹Institut für Pathologie, Universität Würzburg. thomas.ruediger@mail.uni-wuerzburg.de

|December 18, 2002

Summary

Malignant lymphomas are complex cancers. New classifications and diverse therapies improve patient survival and quality of life, emphasizing the need for participation in clinical studies for optimal treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Ectopic thymic tissue and ectopic thymic tumors].

Der Pathologe·2018

Same author

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Same author

[Certified further education in Der Pathologe].

Der Pathologe·2013

Same author

[The bovine cartilage punch model: a tool for the in vitro analysis of biomaterials and cartilage regeneration].

Der Orthopade·2013

Same author

[Primitive neuroectodermal tumor of the testis. Molecular analysis and discussion of genesis].

Der Pathologe·2012

Same author

[Reflections of a Virchow medal laureate].

Der Pathologe·2011

Area of Science:

Hematology
Oncology
Immunology

Context:

Malignant lymphomas are a complex group of neoplasms due to lymphocyte development and immune system intricacies.
The KIEL-classification's clinical grouping of high-grade versus low-grade lymphomas is outdated and potentially misleading.
Mantle cell lymphoma, morphologically low-grade, exhibits an aggressive clinical course, highlighting classification limitations.

Purpose:

To discuss the complexity of malignant lymphomas and the evolution of their classification.
To highlight the limitations of older classifications like KIEL in defining lymphoma behavior.
To emphasize the advancements in therapy and the importance of clinical studies for malignant lymphomas.

Summary:

The WHO classification has replaced the KIEL classification due to its misleading nature, particularly for lymphomas like mantle cell lymphoma.
Therapeutic strategies for malignant non-Hodgkin lymphomas have diversified significantly.
Clinical studies have led to substantial improvements in survival and quality of life for lymphoma patients.

Impact:

Improved understanding of lymphoma heterogeneity and clinical behavior.
Advancement of standardized diagnostic and therapeutic protocols for lymphomas.
Enhanced patient outcomes through optimized treatment strategies within clinical trials.

Related Experiment Videos